← ANALYST RATINGS · TIPRANKS
Abeona Therapeutics (ABEO): analyst forecast and price target
Analyst consensus
Moderate Buy2 Buy0 Hold0 Sell
Ratings of 2 analysts in the last 3 months · top analysts only12-month forecast
Based on 2 price targets given in the last 3 months, the average target is $25.00, the highest $30.00, the lowest $20.00. The average is +464.3% from the last price of $4.43.
Analyst ratings 7
| Analyst | Firm | Price target | Rating | Upside | Action | Date | Move vs SPY | |
|---|---|---|---|---|---|---|---|---|
| AI xAi BiotechnologyxAI Grok-4 | TipRanks - xAI | $5.00 → $4.50−10.0% | Hold | +1.6% | Downgrade | 16.10.26on TipRanks Oct 15 23:05 | — | |
| AI DeepSeek BiotechnologyDeepSeek V3.2-Speciale | TipRanks - DeepSeek | $5.00 → $4.50−10.0% | Hold | +1.6% | Reiterated | 16.10.26on TipRanks Oct 15 23:05 | — | |
| AI OpenAI BiotechnologyOpenAI 5.2 | TipRanks - OpenAI | $5.00 → $4.50−10.0% | Hold | +1.6% | Reiterated | 16.10.26on TipRanks Oct 15 23:05 | — | |
| AI Anthropic BiotechnologyAnthropic Opus-4.6 | TipRanks - Anthropic | $5.00 → $4.00−20.0% | Hold | −9.7% | Reiterated | 16.10.26on TipRanks Oct 15 23:05 | — | |
| AI Google BiotechnologyGemini 3.1Pro | TipRanks - Google | $5.00 → $4.50−10.0% | Hold | +1.6% | Reiterated | 16.10.26on TipRanks Oct 15 23:05 | — | |
| AI PerPlexity BiotechnologyPerPlexity SonarPro | TipRanks - PerPlexity | $5.00 → $4.50−10.0% | Hold | +1.6% | Downgrade | 16.10.26on TipRanks Oct 15 23:05 | — | |
| AI xAi BiotechnologyxAI Grok-4 | TipRanks - xAI | $5.50 → $5.00−9.1% | Hold | +12.9% | Downgrade | 10.10.26on TipRanks Oct 9 23:05 | — | |
| AI DeepSeek BiotechnologyDeepSeek V3.2-Speciale | TipRanks - DeepSeek | $5.50 → $5.00−9.1% | Hold | +12.9% | Reiterated | 04.10.26on TipRanks Oct 3 23:05 | — | |
| AI Google BiotechnologyGemini 3.1Pro | TipRanks - Google | $5.50 → $5.00−9.1% | Hold | +12.9% | Reiterated | 04.10.26on TipRanks Oct 3 23:05 | — | |
| AI PerPlexity BiotechnologyPerPlexity SonarPro | TipRanks - PerPlexity | $5.50 → $5.00−9.1% | Hold | +12.9% | Downgrade | 04.10.26on TipRanks Oct 3 23:05 | — | |
| AI xAi BiotechnologyxAI Grok-4 | TipRanks - xAI | $5.50 | Hold | +24.2% | Downgrade | 30.09.26on TipRanks Sep 29 23:05 | — | |
| AI DeepSeek BiotechnologyDeepSeek V3.2-Speciale | TipRanks - DeepSeek | $5.50 | Hold | +24.2% | Reiterated | 30.09.26on TipRanks Sep 29 23:05 | — | |
| AI OpenAI BiotechnologyOpenAI 5.2 | TipRanks - OpenAI | $5.50 → $5.00−9.1% | Hold | +12.9% | Reiterated | 30.09.26on TipRanks Sep 29 23:05 | — | |
| AI Anthropic BiotechnologyAnthropic Opus-4.6 | TipRanks - Anthropic | $5.00 | Hold | +12.9% | Reiterated | 30.09.26on TipRanks Sep 29 23:05 | — | |
| AI Google BiotechnologyGemini 3.1Pro | TipRanks - Google | $5.50 | Hold | +24.2% | Reiterated | 30.09.26on TipRanks Sep 29 23:05 | — | |
| AI PerPlexity BiotechnologyPerPlexity SonarPro | TipRanks - PerPlexity | $5.50 | Hold | +24.2% | Downgrade | 30.09.26on TipRanks Sep 29 23:05 | — | |
| Ram Selvaraju★★★★★★★★★★#212 · hits 57% · avg +24.4% | H.C. Wainwright | $20.00 | Buy | +351.5% | Reiterated | 25.09.26on TipRanks 06:30 | −1.1%next day −1.3% · 5 days −6.6% | ↗ |
| Boobalan Pachaiyappan★★★★★★★★★★#11894 · hits 38% · avg −7.5% | Roth MKM | $17.00 | Buy | +283.7% | Initiated | 19.09.26on TipRanks Sep 17 04:40 | +3.0%next day −0.5% · 5 days −3.7% | ↗ |
| Kristen Kluska★★★★★★★★★★#457 · hits 48% · avg +23.3% | Cantor Fitzgerald | $28.00 → $30.00+7.1% | Buy | +577.2% | Reiterated | 17.09.26on TipRanks Sep 18 07:45 | +3.0%next day −0.5% · 5 days −3.7% | ↗ |
| Unknown Analyst | Oppenheimer | $21.00 | Buy | +374.0% | Reiterated | 14.08.26on TipRanks Aug 17 21:10 | −5.5%next day −0.3% · 5 days +3.1% | ↗ |
| Unknown Analyst | Jefferies | $17.00 | Buy | +283.7% | Reiterated | 14.05.26on TipRanks 13:06 | −2.7%next day −0.8% · 5 days −0.7% | ↗ |
| James Molloy★★★★★★★★★★#12352 · hits 25% · avg −19.8% | Alliance Global Partners | $20.00 | Buy | +351.5% | Reiterated | 13.05.26on TipRanks 12:50 | 0.0%next day −2.7% · 5 days −6.7% | ↗ |
| Stephen Willey★★★★★★★★★★#1608 · hits 45% · avg +8.1% | Stifel Nicolaus | $17.00 | Buy | +283.7% | Reiterated | 18.03.26on TipRanks 22:06 | 0.0%next day −0.5% · 5 days −2.7% | ↗ |
| No ratings for this filter. | ||||||||
Every rating the collector has kept for the last 12 months, including the earlier ones of the same analyst. Latest of each analyst
Best analysts covering Abeona Therapeutics
TipRanks picks them by their record on this stock; the figures under the name are their record across all their ratings.
Most accurate
Most profitable
How the average price target moved
The average target of all analysts (their ratings of the 3 months before) on each day, the top analysts’ dashed, against the price; the site keeps this record since 1 October 2026. On 01.10.26: target $22.00 at a price of $5.25 (+319.0%); now: $22.00 at $4.43 (+396.6%).
PriceAverage targetTop analysts’ target
Recommendation trend · top analysts
Strong BuyBuyHoldSell
| Rating | 05.26 | 06.26 | 07.26 | 08.26 | 09.26 | 10.26 |
|---|---|---|---|---|---|---|
| Strong Buy | 1 | 0 | 0 | 0 | 1 | 1 |
| Buy | 0 | 0 | 0 | 0 | 0 | 0 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
Earnings and sales forecast
Next report: 16.11.26 (Q3 2026, date not confirmed)
Earnings per share
Next quarter’s EPS estimate — $-0.17 (from $-0.25 to $-0.05). Last quarter: $-0.35.
Sales
Next quarter’s sales estimate — $15M (from $11M to $22M). Last quarter: $11M.
Best top-analyst consensus in the sector · Healthcare
About Abeona Therapeutics
- CEO: Vishwas Seshadri
- Employees: 226
- 6555 Carnegie Avenue, Cleveland, OH, 44103, US
- www.abeonatherapeutics.com
Abeona Therapeutics Inc. is a biopharmaceutical company in the clinical development stage, focused on creating innovative gene and cell therapies to address severe and uncommon genetic diseases. Its leading program, EB-101, an autologous gene-corrected cell therapy, is presently in a Phase III clinical trial for treating recessive dystrophic epidermolysis bullosa. The company's pipeline also features several other promising therapies: ABO-102, an adeno-associated virus (AAV)-based gene therapy for Sanfilippo syndrome type A. ABO-201, intended for CLN3 disease. ABO-401, developed to treat cystic fibrosis. ABO-50X, aimed at various genetic eye disorders. Additionally, Abeona is advancing AAV-based gene therapy solutions through its proprietary AIM vector platform. The company, which was founded in 1974 and is headquartered in New York, New York, changed its name to Abeona Therapeutics Inc. in June 2015, having previously been known as PlasmaTech Biopharmaceuticals, Inc.
Data from the stock’s TipRanks forecast page, read 82 min ago. It is read again as soon as a new rating appears and at least every 8 hours. TipRanks ↗